rivastigmine has been researched along with Disease Exacerbation in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.04) | 18.2507 |
| 2000's | 32 (65.31) | 29.6817 |
| 2010's | 14 (28.57) | 24.3611 |
| 2020's | 2 (4.08) | 2.80 |
| Authors | Studies |
|---|---|
| Cucos, CA; Dobre, M; Dragnea, EM; Manda, G; Milanesi, E | 1 |
| Honjo, Y; Ide, K; Takechi, H | 1 |
| Bonnet, U; Knierim, U; Stuehler, L; Taha, S | 1 |
| Adorni, F; Caltagirone, C; Di Santo, SG; Musicco, M; Prinelli, F | 1 |
| Bahrammi, MA; Naghibis, SN; Nasab, NM; Nikpour, MR; Rahim, F | 1 |
| Andreozzi, P; Artini, M; Bechini, F; Cerra, E; De Angelis, R; Ettorre, E; Pontecorvo, ML; Selan, L; Servello, A; Vigliotta, MT; Vulcano, A | 1 |
| Shoji, M | 1 |
| Batistela, MS; Bono, GF; Dias, PF; Furtado-Alle, L; Josviak, ND; Nascimento, GA; Piovezan, MR; Simão-Silva, DP; Souza, RK; Souza, RL | 1 |
| Isik, AT; Soysal, P | 1 |
| Chouliaras, L; Hickey, L; Nour, JM | 1 |
| Ruis, J | 1 |
| Lane, R; Venneri, A | 1 |
| Bullock, R; Hatoum, HT; Lane, R; Lin, SJ; Thomas, SK | 1 |
| Adler, CH; Almaraz, AC; Caselli, RJ; Caviness, JN; Demaerschalk, BM; Driver-Dunckley, ED; Wellik, KE; Wingerchuk, DM; Woodruff, BK | 1 |
| Darreh-Shori, T; Ferris, S; Lane, R; Nordberg, A; Soininen, H | 1 |
| Farlow, M; Feldman, HH; Ferris, S; Lane, R; Sfikas, N; Winblad, B | 1 |
| Leifer, BP | 1 |
| Akehurst, R; Brandtmüller, A; Brennan, A; Nagy, B; Sullivan, SD; Thomas, SK | 1 |
| Berrut, G; Bourdeix, I; Carcaillon, L; Dartigues, JF; Gillette, S; Pere, JJ; Sellal, F | 1 |
| Natali, B; Taffet, GE; Wagle, KC | 1 |
| Atri, A | 1 |
| Aisen, PS; Cummings, J; Schneider, LS | 1 |
| Bakchine, S; Bellelli, G; Black, SE; Caputo, A; Cummings, J; Downs, P; Froelich, L; Kressig, RW; Molinuevo, JL; Strohmaier, C | 1 |
| Farlow, MR | 1 |
| Retz, W; Retz-Junginger, P; Rösler, M; Supprian, T; Wobrock, T | 1 |
| Gabelli, C | 1 |
| Akkawi, N; Bordonali, T; Borroni, B; Di Luca, M; Padovani, A; Pettenati, C | 1 |
| Andrews, C; Erkinjuntti, T; Lane, R; Skoog, I | 1 |
| Amaya, K; Casciano, J; Casciano, R; Chang, S; Cheng, I; Cuccia, AJ; Marin, D; Puder, KL; Snyder, EH | 1 |
| Ferrara, R; McKeith, IG; Perry, E; Wesnes, KA | 1 |
| Press, DZ | 1 |
| Appels, BA; Beijnen, JH; de Boer, A; Frankfort, SV; Koks, CH; Tulner, LR; van Campen, JP | 1 |
| Ownby, RL | 1 |
| Johannsen, P | 1 |
| Burns, A; Charles, HC; Cummings, J; del Ser, T; Farlow, M; Feldman, HH; Ferris, S; Fox, NC; He, Y; Herrmann, N; Inzitari, D; Lane, R; Mancione, L; Orgogozo, JM; Potkin, S; Sauer, H; Scarpini, E; Scheltens, P; Sfikas, N; Tekin, S; Winblad, B | 1 |
| Damier, P; Meyniel, C | 1 |
| Green, C | 1 |
| Neno, R | 1 |
| Clerici, F; Elia, A; Maggiore, L; Mariani, C; Pomati, S; Ratti, PL | 1 |
| Liao, S; Morrison, LJ | 1 |
| Agid, Y; Anand, R; Cicin-Sain, A; Dal-Bianco, P; Gauthier, S; Gharabawi, M; Hartman, R; Rösler, M; Stähelin, HB | 1 |
| Gnanasakthy, A; Hauber, AB; Mauskopf, JA | 1 |
| Anand, R; Farlow, M; Hartman, R; Messina, J; Veach, J | 1 |
| Anand, R; Farlow, MR; Hake, A; Hartman, R; Messina, J; Veach, J | 1 |
| Sternon, J; Ventura, M | 1 |
| Barcikowska, M; Bilikiewicz, A; Bilińska, M; Gabryelewicz, T; Ochudło, S; Opala, G; Paradowski, B; Parnowski, T; Pfeffer, A; Podemski, R; Puzyński, S; Sołtys, K; Łapin, J | 1 |
| Lechner, A; Petrovic, K; Schmidt, R | 1 |
| Cherry, D; Cummings, JL; Frank, JC; Hewett, L; Kemp, B; Kohatsu, ND; Mittman, B | 1 |
| Robert, P | 1 |
13 review(s) available for rivastigmine and Disease Exacerbation
| Article | Year |
|---|---|
A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Cognition; Data Interpretation, Statistical; Disability Evaluation; Disease Progression; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2013 |
[Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Cognitive Dysfunction; Dementia; Disease Progression; Donepezil; Education, Medical, Continuing; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Peptide Fragments; Phenylcarbamates; Piperidines; Positron-Emission Tomography; Reference Standards; Rivastigmine; tau Proteins; Tomography, Emission-Computed, Single-Photon | 2014 |
Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia.
Topics: Acetylcholine; Administration, Oral; Aged; Brain; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Humans; Lewy Body Disease; Male; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Placebos; Rivastigmine; Treatment Outcome | 2009 |
Effective pharmacological management of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome | 2011 |
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
Topics: Alkaloids; Alzheimer Disease; Amino Acids; Animals; Cholinesterase Inhibitors; Dietary Supplements; Disease Progression; Docosahexaenoic Acids; Donepezil; Drug Approval; Galantamine; Ginkgo biloba; Half-Life; History, 20th Century; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Psychotropic Drugs; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Sesquiterpenes; Vitamin B Complex; Vitamin E | 2012 |
Do cholinesterase inhibitors slow progression of Alzheimer's disease?
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Humans; Nootropic Agents; Phenylcarbamates; Rivastigmine | 2002 |
Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cognition; Disease Progression; Economics, Pharmaceutical; Humans; Mental Disorders; Meta-Analysis as Topic; Neuroprotective Agents; Phenylcarbamates; Risk Factors; Rivastigmine; Treatment Outcome | 2003 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Dementia, Vascular; Disease Progression; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Lewy Body Disease; Memantine; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2006 |
[Lewy body dementia and Parkinson disease dementia].
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Dementia; Diagnosis, Differential; Disease Progression; Dopamine Agents; Humans; Iatrogenic Disease; Levodopa; Lewy Body Disease; Neuroprotective Agents; Nootropic Agents; Parkinson Disease; Parkinsonian Disorders; Phenylcarbamates; Psychotropic Drugs; Rivastigmine; Serotonin Antagonists | 2007 |
Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Models, Economic; Phenylcarbamates; Piperidines; Rivastigmine | 2007 |
[Anticholinesterase agents in Alzheimer's disease].
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carbamates; Cholinesterase Inhibitors; Diagnosis, Differential; Disease Progression; Donepezil; Drug Therapy, Combination; Estrogen Replacement Therapy; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Treatment Outcome | 2001 |
Guidelines for managing Alzheimer's disease: Part II. Treatment.
Topics: Advance Directives; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Donepezil; Humans; Indans; Lorazepam; Patient Education as Topic; Phenylcarbamates; Piperidines; Risperidone; Rivastigmine | 2002 |
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Topics: Acetylcholine; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Disease Progression; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Phenylcarbamates; Physostigmine; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome | 2002 |
16 trial(s) available for rivastigmine and Disease Exacerbation
| Article | Year |
|---|---|
Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Disease Progression; Double-Blind Method; Female; Ginkgo biloba; Humans; Male; Middle Aged; Phenylcarbamates; Phytotherapy; Rivastigmine; Treatment Outcome | 2012 |
Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.
Topics: Alzheimer Disease; Biomarkers; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Progression; Female; Genotype; Humans; Male; Neuroprotective Agents; Pharmacogenetics; Phenylcarbamates; Placebos; Retrospective Studies; Rivastigmine; Treatment Outcome | 2009 |
Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Disease Progression; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Proportional Hazards Models; Rivastigmine; Sex Factors | 2009 |
Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.
Topics: Alzheimer Disease; Brief Psychiatric Rating Scale; Cost-Benefit Analysis; Disease Progression; Female; Humans; Institutionalization; Male; Models, Economic; Neuroprotective Agents; Phenylcarbamates; Quality-Adjusted Life Years; Regression Analysis; Rivastigmine; Social Support; Transdermal Patch; United Kingdom | 2011 |
Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Phenylcarbamates; Rivastigmine; Transdermal Patch; Treatment Outcome | 2012 |
Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Carbamates; Cholesterol; Cholinesterase Inhibitors; Disease Progression; Donepezil; Female; Genotype; Humans; Indans; Male; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2003 |
Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Female; Humans; Hypertension; Male; Medical Records; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2003 |
Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies.
Topics: Aged; Attention; Carbamates; Disease Progression; Double-Blind Method; Female; Hallucinations; Humans; Lewy Body Disease; Male; Neuroprotective Agents; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Prospective Studies; Reaction Time; Risk Factors; Rivastigmine | 2004 |
Quetiapine and rivastigmine for agitation in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dibenzothiazepines; Disease Progression; Double-Blind Method; Humans; Phenylcarbamates; Psychomotor Agitation; Quetiapine Fumarate; Rivastigmine | 2006 |
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Tremor; Vomiting | 2007 |
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Health Status; Humans; Male; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine | 1999 |
Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
Topics: Aged; Algorithms; Alzheimer Disease; Canada; Carbamates; Cholinesterase Inhibitors; Cognition; Cost Savings; Cost-Benefit Analysis; Disease Progression; Female; Humans; Male; Middle Aged; Models, Economic; Neuroprotective Agents; Phenylcarbamates; Proportional Hazards Models; Psychiatric Status Rating Scales; Quality-Adjusted Life Years; Rivastigmine | 2000 |
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
Topics: Age Factors; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Phenylcarbamates; Rivastigmine; Time Factors; Treatment Outcome | 2000 |
Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Double-Blind Method; Female; Humans; Linear Models; Male; Phenylcarbamates; Predictive Value of Tests; Prognosis; Rivastigmine; Treatment Outcome | 2001 |
An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Disease Progression; Female; Humans; Male; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2002 |
Rivastigmine in outpatient services: experience of 114 neurologists in Austria.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Austria; Carbamates; Cognition; Disease Progression; Female; Humans; Male; Neuroprotective Agents; Neuropsychological Tests; Outpatients; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine; Treatment Outcome | 2002 |
20 other study(ies) available for rivastigmine and Disease Exacerbation
| Article | Year |
|---|---|
Increased MYD88 blood transcript in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Disease Progression; Humans; Inflammation; Mice; Mice, Transgenic; Myeloid Differentiation Factor 88; Rivastigmine | 2022 |
Medical interventions suppressed progression of advanced Alzheimer's disease more than mild Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progression; Donepezil; Female; Galantamine; Humans; Japan; Male; Memantine; Mental Status and Dementia Tests; Retrospective Studies; Rivastigmine | 2020 |
The transition from vivid dreams over floccillations and visual hallucinations to complete delirium in a geriatric patient at the dawn of Alzheimer's dementia: beneficial role of rivastigmine.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Delirium; Disease Progression; Hallucinations; Humans; Male; Rivastigmine | 2019 |
[Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)].
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Disease Progression; Female; Humans; Male; Mental Status Schedule; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2014 |
Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population.
Topics: Alzheimer Disease; Brazil; Butyrylcholinesterase; Case-Control Studies; Cholinesterase Inhibitors; Disease Progression; Humans; Rivastigmine | 2015 |
Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study.
Topics: Acetylcholinesterase; Activities of Daily Living; Aged; Body Mass Index; Body Weight; Cholinesterase Inhibitors; Dementia; Disease Progression; Donepezil; Eating; Female; Follow-Up Studies; Galantamine; Geriatric Assessment; Humans; Indans; Male; Nutrition Assessment; Nutritional Status; Piperidines; Polypharmacy; Retrospective Studies; Rivastigmine | 2016 |
High dose rivastigmine in the symptom management of Lewy body dementia.
Topics: Aged; Cholinesterase Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Humans; Lewy Body Disease; Male; Phenylcarbamates; Quality of Life; Rivastigmine; Treatment Outcome | 2016 |
[Alzheimer type dementia].
Topics: Alzheimer Disease; Apolipoprotein E4; Diagnosis, Differential; Disease Progression; Donepezil; Humans; Indans; Memantine; Neuroprotective Agents; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Risk Factors; Rivastigmine | 2008 |
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Cholinesterase Inhibitors; Cytoprotection; Disease Progression; Donepezil; Drug Synergism; Drug Therapy, Combination; Female; Galantamine; Humans; Image Processing, Computer-Assisted; Indans; Magnetic Resonance Imaging; Male; Nerve Fibers, Myelinated; Neural Pathways; Neuroprotective Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2009 |
Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Female; Forecasting; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Nursing Homes; Patient Transfer; Phenylcarbamates; Piperidines; Proportional Hazards Models; Prospective Studies; Psychometrics; Randomized Controlled Trials as Topic; Risk Assessment; Rivastigmine; Severity of Illness Index | 2009 |
Alzheimer's disease: Seeing the signs early.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Galantamine; Humans; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Primary Health Care; Psychometrics; Rivastigmine; Time Factors | 2009 |
Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Disease Progression; Educational Status; Female; Geriatric Assessment; Humans; Institutionalization; Logistic Models; Male; Memantine; Middle Aged; Observation; Phenylcarbamates; Qualitative Research; Risk Factors; Rivastigmine; Surveys and Questionnaires | 2011 |
Cholinesterase inhibitor initiation in hospital setting.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Delirium; Diagnosis, Differential; Disease Progression; Early Termination of Clinical Trials; Hospitalization; Humans; Intensive Care Units; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine | 2011 |
[Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
Topics: Affective Disorders, Psychotic; Aged; Aged, 80 and over; Alzheimer Disease; Anxiety Disorders; Carbamates; Cholinesterase Inhibitors; Cognition; Disease Progression; Female; Hallucinations; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine | 2003 |
Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Caregivers; Cholinesterase Inhibitors; Cohort Studies; Cost of Illness; Cost Savings; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Health Expenditures; Humans; Institutionalization; Mental Status Schedule; New York City; Phenylcarbamates; Prospective Studies; Psychometrics; Rivastigmine | 2003 |
Parkinson's disease dementia--a first step?
Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Disease Progression; Humans; Lewy Body Disease; Nausea; Parkinson Disease; Phenylcarbamates; Rivastigmine | 2004 |
Discontinuation of rivastigmine in routine clinical practice.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Patient Dropouts; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine; Treatment Failure | 2005 |
NICE judgement leaves behind a nasty taste.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Formularies as Topic; Galantamine; Humans; Indans; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Jurisprudence; Phenylcarbamates; Piperidines; Rivastigmine; State Medicine; Time Factors; United Kingdom | 2007 |
Cholinergic balance in dementia with Lewy bodies: reversible worsening of Parkinsonism at rivastigmine dosage modulation.
Topics: Acetylcholine; Aged; Cholinesterase Inhibitors; Disease Progression; Humans; Lewy Body Disease; Male; Parkinsonian Disorders; Phenylcarbamates; Rivastigmine; Time Factors | 2007 |
Dementia medications in palliative care #174.
Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Palliative Care; Phenylcarbamates; Piperidines; Prognosis; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2008 |